Every 10-Q that Aclarion, Inc. Warrant (ACONW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ACONW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACONW filings page.
Aclarion, Inc., an early-stage healthcare technology company, generated modest revenue but continued sizable losses in the quarter ended June 30, 2026. Q2 revenue was $25,208 (first-half $46,348), while net losses were $2.7 million for the quarter and $5.6 million year‑to‑date.
Operating expenses rose sharply as the company invested in commercialization and product development. First-half operating expenses reached $5.9 million, driven by higher sales and marketing spending around the NOCISCAN report and CLARITY Trial, increased R&D, and greater legal, investor relations, and Delaware franchise tax costs.
Despite negative operating cash flow of $5.3 million in the first half, Aclarion strengthened its balance sheet via a January 2026 registered direct offering of common stock and pre-funded warrants, raising about $10.4 million. Cash, cash equivalents and restricted cash totaled $16.3 million at June 30, 2026, and management believes this will fund operations for at least twelve months, though additional capital may be needed to fully execute its strategy. Common shares outstanding increased to 2,462,250 at June 30, 2026, reflecting equity financings and warrant exercises.
Aclarion, Inc. reported a larger net loss for the quarter ended March 31, 2026, while significantly strengthening its cash position through new equity financing. Revenue rose modestly to $21,140 from $18,991, driven mainly by more Nociscan reports sold in the U.K.
Operating expenses nearly doubled to $2.99 million, reflecting higher sales and marketing spending around the CLARITY Trial, greater research and development, and increased general and administrative costs such as investor relations and Delaware franchise taxes. Net loss widened to $2.85 million from $2.04 million, or $(1.34) per share.
Cash, cash equivalents and restricted cash increased to $19.03 million, supported by a January 2026 registered direct offering of common stock and pre-funded warrants that generated roughly $10.4 million in gross proceeds. The company expects its current cash to fund operations into the second half of 2027. Subsequent to quarter-end, the board approved a $2.5 million share repurchase program and adopted a stockholder rights agreement intended to discourage hostile accumulations of its stock.
Aclarion, Inc. reported results for the quarter ended June 30, 2025. Cash and cash equivalents were $12,850,657 (including $11,949,908 in money market funds), which management believes funds operations into the third quarter of 2026. Revenue grew to $19,319 in Q2 2025 (up 76% year-over-year) and $38,309 for the six months (up 82%), driven by increased NOCISCAN report volume in the U.K. Q2 gross profit was $5,140, but operating expenses rose to $1.74 million, producing a Q2 net loss of $1.60 million and a six-month net loss of $3.64 million. In H1 2025 the company raised approximately $20.1 million via a public unit offering, two registered direct offerings and warrant exercises. Corporate actions included two 2025 reverse stock splits and the $1,213,590 redemption of Series B preferred stock. The company recorded a $687,500 settlement in March 2025. Readers should consult the full notes for detailed terms of warrants, preferred conversions, and cash assumptions.